FDA Approves Pembrolizumab for Treatment of Certain Patients with NMIBC

The FDA approved pembrolizumab for the treatment of patients with BCG –unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in-situ with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.

Source: CancerNetwork - January 8, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news